{Amatuximab | This cutting-edge antibody, designated MORab-009, represents a promising advancement in targeted therapy. The drug is a humanized monoclonal antibody specifically engineered to attach to CD33 , a protein highly expressed
Tisotumabs was the important research method for examining antibodies behavior. In its unique composition allows researchers to explore characteristics of antibodies interaction and effector processes. Moreover, tisotumabs can be applied t
Carfilzomib represents a novel proteasome inhibitor utilized in the struggle against cancer. It drug operates by interfering with the activity of the proteasome, a cellular complex responsible for the breakdown of proteins. By inhibiting this mechanism, carfilzomib leads the buildup of damaged or
Compound E, chemically designated as 209986-17-4, represents a significant exploration within the field of Alzheimer's disease research. This γ-secretase blocking agent was initially developed as a promising therapeutic approach aimed at reducing the generation of amyloid-beta copyright, which are